期刊
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
卷 321, 期 2, 页码 R250-R259出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpregu.00337.2020
关键词
amylin; dorsal vagal complex; hindbrain; obesity; pharmacotherapy
类别
资金
- Zealand Pharma
- Boehringer-Ingelheim
- National Institutes of Health [DK105155]
ZP5461 shows potential in reducing food intake and body weight in rats, but it fails to sustainably suppress intake and weight gain in the long term. The activation of DVC CTRs plays a significant role in the early reductions in intake and weight gain caused by chronic systemic ZP5461 administration. Future studies are needed to explore alternative dosing regimens of ZP5461 for prolonged body weight suppression.
The peptide hormone amylin reduces food intake and body weight and is an attractive candidate target for novel pharmacotherapies to treat obesity. However, the short half-life of native amylin and amylin analogs like pramlintide limits these compounds' potential utility in promoting sustained negative energy balance. Here, we evaluate the ability of the novel long-acting amylin/calcitonin receptor agonist ZP5461 to reduce feeding and body weight in rats, and also test the role of calcitonin receptors (CTRs) in the dorsal vagal complex (DVC) of the hindbrain in the energy balance effects of chronic ZP5461 administration. Acute dose-response studies indicate that systemic ZP5461 (0.5-3 nmol/kg) robustly suppresses energy intake and body weight gain in chow-and high-fat diet (HFD)-fed rats. When HFD-fed rats received chronic systemic administration of ZP5461 (1-2 nmol/kg), the compound initially produced reductions in energy intake and weight gain but failed to produce sustained suppression of intake and body weight. Using virally mediated knockdown of DVC CTRs, the ability of chronic systemic ZP5461 to promote early reductions in intake and body weight gain was determined to be mediated in part by activation of DVC CTRs, implicating the DVC as a central site of action for ZP5461. Future studies should address other dosing regimens of ZP5461 to determine whether an alternative dose/frequency of administration would produce more sustained body weight suppression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据